The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

FDA APPROVES KYPROLIS® (CARFILZOMIB) FOR COMBINATION USE IN THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA

THOUSAND OAKS, Calif. (July 24, 2015) – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Kyprolis® (carfilzomib) for Injection in combination with Revlimid® (lenalidomide) and dexamethasone (KRd) for the treatment of patients with multiple myeloma who have received one to three prior lines of therapy. READ MORE

Posted: July 28, 2015

Collaborating Toward a Cure

We’ve seen how dramatically patients’ lives can change when they are matched with the right treatment at the right time in their disease course. Although this is still an exception and not the rule, we believe collaborative research approaches will make this kind of precision medicine a reality for all patients with cancers. READ MORE

Posted: July 28, 2015

Immunotherapy: Helping the Immune System Identify and Fight Cancer

Cancer cells, compared to foreign invaders, are more difficult for the immune system to identify and recognize as toxic because they originate from an individual’s own cells. Using drugs to help the immune system attack and fight cancer cells is a fairly new approach, and is based on emerging knowledge about the ways in which the immune system interacts with cancer cells. READ MORE

Posted: June 29, 2015

Page 52 of 87« First...102030...5051525354...607080...Last »